WO2003013270A2 - Calcium dietary supplement - Google Patents

Calcium dietary supplement Download PDF

Info

Publication number
WO2003013270A2
WO2003013270A2 PCT/US2002/025146 US0225146W WO03013270A2 WO 2003013270 A2 WO2003013270 A2 WO 2003013270A2 US 0225146 W US0225146 W US 0225146W WO 03013270 A2 WO03013270 A2 WO 03013270A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight
composition
parts
calcium
vitamin
Prior art date
Application number
PCT/US2002/025146
Other languages
French (fr)
Other versions
WO2003013270A3 (en
Inventor
Hendricks Lewis
Original Assignee
Rhodia Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodia Inc. filed Critical Rhodia Inc.
Priority to AU2002331013A priority Critical patent/AU2002331013A1/en
Publication of WO2003013270A2 publication Critical patent/WO2003013270A2/en
Publication of WO2003013270A3 publication Critical patent/WO2003013270A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5929,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof

Definitions

  • This invention relates to dietary supplements, more particularly to calcium-containing dietary supplements.
  • Mineral and vitamin compositions are routinely used as dietary supplements, either as general nutritional supplements or as therapeutic preparations directed to treat specific medical problems.
  • Osteoporosis is an important nutrient for growing children to help in bone formation and for adults to help prevent bone loss. Excessive bone loss may lead to a condition known as "osteoporosis", in which decreased bone mass causes the bones to be more brittle and thus more susceptible to fracture. It is widely believed that a chronic shortage of dietary calcium is one factor leading to osteoporosis, see Osteoporosis, Cause,
  • Calcium dietary supplements appear to be of value in helping to prevent osteoporosis.
  • HRT hormone replacement therapy
  • raloxifene hydrochloride raloxifene hydrochloride
  • Raloxifene hydrochloride belongs to a class of drugs described as selective estrogen receptor modulators, and in addition to its well documented benefits in the treatment of osteoporosis, it has been shown in two randomized trials on post-menopausal women to reduce Hey levels (see Saitta A et al, "Cardiovascular effects of raloxifene hydrochloride", Cardiovasc Drug Rev 2001 Spring;19(1):57-74).
  • the present invention is directed to a dietary supplement composition, comprising phosphorus and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus.
  • the present invention is directed to a particulate dietary supplement composition, comprising phosphorus and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus.
  • the present invention is directed to a directly compressible dietary supplement composition, comprising phosphorus, from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus, a dissolution aid and a lubricant, wherein said directly compressible dietary supplement composition is capable of being directly compressed to form tablet of dietary supplement composition.
  • the present invention is directed to a dietary supplement composition in tablet form, comprising calcium and phosphorus, wherein the tablet has a total weight of from 400 to 2000 milligrams per tablet and comprises greater than about 200 milligrams calcium per tablet and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus.
  • the present invention is directed to a liquid dietary supplement composition, comprising calcium and phosphorus, wherein the liquid comprises greater than about 100 milligrams calcium per 100 milliliters of liquid and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus.
  • the present invention is directed a dietary supplement composition
  • a dietary supplement composition comprising phosphorus, from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus and a compound selected from Vitamin D, Vitamin B 12 , folate and Vitamin B 6 .
  • the supplement composition of the present invention provides supplemental calcium and phosphorus in the relative amounts required to simultaneously correct the calcium and phosphorus deficiencies which characterize the demographic group of those women greater than 31 years of age that are in the 50 th percentile or lower in calcium and phosphorus intake.
  • the supplement composition of the present invention combines the benefits of supplemental calcium and phosphorus in the above described ratios with the effects of certain B-complex vitamins to provide further benefit in the prevention of osteoporosis in men and women.
  • the dietary supplement composition of the present invention comprises greater than about 20 parts by weight (“pbw”), more preferably from about 25 to about 35 pbw, and even more preferably from 28 to about 32 pbw calcium per 100 pbw of the supplement composition.
  • the supplement composition of the present invention comprises from about 1.4 to about 2.1 pbw, more preferably from about 1.5 to about 2.0 pbw, calcium per pbw phosphorus.
  • the calcium component of the supplement composition of the present invention comprises one or more of calcium chelates, such as for example, calcium proteinate, and calcium salts, such as, for example, calcium carbonate, calcium gluconate, calcium citrate, tricalcium phosphate, or dicalcium phosphate dihydrate or anhydrous dicalcium phosphate, calcium citrate maleate.
  • calcium chelates such as for example, calcium proteinate
  • calcium salts such as, for example, calcium carbonate, calcium gluconate, calcium citrate, tricalcium phosphate, or dicalcium phosphate dihydrate or anhydrous dicalcium phosphate, calcium citrate maleate.
  • the phosphorus component of the supplement composition of the present invention comprises one or more of phosphate salts, such as for example, tricalcium phosphate, or dicalcium phosphate dihydrate or anhydrous dicalcium phosphate, sodium phosphate, and proteins, such as, for example, soy protein, whey protein.
  • phosphate salts such as for example, tricalcium phosphate, or dicalcium phosphate dihydrate or anhydrous dicalcium phosphate, sodium phosphate
  • proteins such as, for example, soy protein, whey protein.
  • the phosphorus component and a portion of the calcium component of the supplement composition of the present invention are supplied as a calcium phosphate salt, such as for example, tricalcium phosphate, dicalcium phosphate dihydrate, anhydrous dicalcium phosphate, monocalcium phosphate.
  • the calcium and phosphorus components are each in the form of particles, more preferably particles having an average particle size of from about 180 to about 350 micrometers ( ⁇ m).
  • the dietary supplement composition of the present invention comprises anhydrous dicalcium phosphate, tricalcium phosphate and calcium carbonate.
  • the dietary supplement composition of the present invention comprises, based on 100 pbw of the composition, from about 50 to about 70 pbw, more preferably from about 56 to about 65 pbw, and even more preferably from about 59 to about 62 pbw, anhydrous dicalcium phosphate, from about 24 to about 40 pbw, more preferably from about 28 to about 36 pbw, and even more preferably from about 31 to about 33 pbw, tricalcium phosphate and from about 3 to about 11 pbw, more preferably from about 5 to about 9 pbw, and even more preferably from about 6 to about 8 pbw, calcium carbonate.
  • the dietary supplement composition is capable of being directly compressed to form a compressed oral dosage from, such as, for example, a tablet or caplet, and comprises, based on 100 pbw of the composition, from about 50 to about 70 pbw, more preferably from about 56 to about 65 pbw, and even more preferably from about 59 to about 62 pbw, anhydrous dicalcium phosphate, from about 24 to about 40 pbw, more preferably from about 28 to about 36 pbw, and even more preferably from about 31 to about 33 pbw, tricalcium phosphate and from about 3 to about 11 pbw, more preferably from about 5 to about 9 pbw, and even more preferably from about 6 to about 8 pbw, calcium carbonate, from about 1 to about 3 pbw dissolution aid, and from about 0.5 to about 2 pbw lubricant.
  • anhydrous dicalcium phosphate from about 24 to about 40 pbw, more preferably from about 28 to
  • the supplement composition further comprises dietary supplemental amounts of vitamins or minerals other than calcium or phosphorus.
  • the supplement composition comprises a dietary supplemental amount of one or more vitamins, such as for example, vitamin D, Vitamin B 6 ; folate and Vitamin B ⁇ 2 , phytoestrogens, such as for example, one or more isoflavones, one or more probiotics and prebiotics, such as for example lactobacillus acidophilus, inulin or other polysaccharides and one or more minerals other than calcium or phosphorus, such as for example, boron, copper, zinc, magnesium, manganese and zinc, that play a role in bone formation and/or bone metabolism.
  • the supplement composition of the present composition may be included as a component of a multi-vitamin and mineral supplement composition.
  • the dietary supplement composition comprises calcium and phosphorus and further comprises one or more of Vitamin D, Vitamin B 6 , folate and Vitamin B- ⁇ 2 .
  • the composition comprises, based on 100 pbw of the composition, from about 6.2 to about 62 pbw, more preferably from about 15.5 to about 47 pbw, and even more preferably from about 29 to about 33 pbw, calcium and from about 6.2 to about 55.7 pbw, more preferably from about 9.3 to about 55.7 pbw and even more preferably from about 16 to about 20 pbw, phosphorus.
  • the composition comprises, based on 100 pbw of the composition, from about 0.000039 to about 0.0012 pbw, more preferably from about 0.00019 to about 0.00062 pbw, and even more preferably from about 0.00025 to about 0.00035 pbw, Vitamin D (as cholecalciferol).
  • the composition comprises, based on
  • composition 100 pbw of the composition, from about 0.03 to about 6.2 pbw, more preferably from about 0.15 to about 4.64 pbw, and even more preferably from about 0.30 to about 0.60 pbw, Vitamin Be.
  • the composition comprises, based on
  • composition 100 pbw of the composition, from about 0.0016 to about 0.062 pbw, more preferably from about 0.0062 to about 0.046 pbw and even more preferably from about 0.025 to about 0.035 pbw, folate (as folic acid);
  • the composition comprises from about
  • Vitamin B- ⁇ 2 (as cyanocobalamin).
  • the supplement composition of the present invention may, optionally, contain other ingredients generally recognized as safe for food additive use, including for example, preservatives, such as, for example, butylated hydroxytoluene, butylated hydroxyanisole, food grade emulsifiers, such as, for example, lecithin, propylene glycol esters, and pharmaceutically acceptable carriers and excipients, such as for example, binders, fillers, lubricants, dissolution aids.
  • the supplement composition of the present invention is made by combining calcium and phosphorus components, as well as any optional components, in the desired relative amounts and mixing the components according to known methods to produce a substantially homogeneous mixture.
  • the present supplement composition may be administered in any oral dosage form, including liquid dosage forms such as, for example, a suspension or slurry, and oral solid dosage forms such as, for example, a tablet or bulk powder.
  • liquid dosage forms such as, for example, a suspension or slurry
  • oral solid dosage forms such as, for example, a tablet or bulk powder.
  • tablette refers generally to tablets, caplets, capsules, including soft gelatin capsules, and lozengers.
  • the supplement composition of the present invention is administered in the form of a tablet. More preferably, the supplemental composition is administered in the form of a tablet of less than or equal to 2 grams per tablet, more preferably from 400 to 1900 mg per tablet, which contains greater than about 225 mg, more preferably from about 250 mg to about 800 mg, calcium per tablet.
  • Tablets are made by methods known in the art and may further comprise suitable binders, lubricants, diluents, disintegrating agents, colorants, flavoring agents, flow-inducing agents, melting agents which are known in the art.
  • the oral solid dosage form may, optionally, have a film coating to protect the components of the supplement composition from one or more of moisture, oxygen and light or to mask any undesirable taste or appearance.
  • Suitable coating agents include, for example, cellulose, hydroxypropylmethyl cellulose.
  • Example 1 The supplement composition of Example 1 was made by mixing 1174.8 grams (g) anhydrous dicalcium phosphate, 629.9 g tricalcium phosphate, 134.7 g calcium carbonate, 40.1 g dissolution aid (AC Dl- SOLTM crosscarmellose sodium) and 20.1 g lubricant (magnesium stearate) in a V-blender. The mixture exhibited a bulk density of 0.859 grams per cubic centimeter and a tamped density of 0.943 grams per cubic centimeter.
  • anhydrous dicalcium phosphate 629.9 g tricalcium phosphate, 134.7 g calcium carbonate
  • 40.1 g dissolution aid AC Dl- SOLTM crosscarmellose sodium
  • 20.1 g lubricant magnesium stearate
  • the mixture was compressed to form tablets of about 950 mg or about 1900 mg each.
  • the 950 mg tablets each contained about 300 mg calcium and 175 mg phosphorus per tablet.
  • the 1900 mg tablets each contained about 600 mg calcium and 350 mg phosphorus per tablet.
  • the dissolution properties of the tablets were determined by ⁇ 711> Dissolution, USP 24, p 1941 (2000) in 0.1 N HCI at 37°C for a test period of 45 minutes. Results are set forth below in TABLE I as tablet weight, expressed in milligrams (mg), results of analysis of the dissolution medium by Inductively Coupled Plasma Spectrophotometer ("ICP Results"), expressed in milligrams of calcium or phosphorus per gram of tablet powder (mg/g), and in milligrams (mg) per 900 milliliters of dissolution medium and the "Label Claim" amount, calculated from the total amount of calcium or phosphorus (in mg) in 900 ml of dissolution medium and expressed as a percentage of the initial tablet weight.
  • ICP Results Inductively Coupled Plasma Spectrophotometer
  • the supplement composition of Example 2 was made by mixing 1148.2 grams (g) anhydrous dicalcium phosphate, 613.7 g tricalcium phosphate, 131.2.7 g calcium carbonate, 0.4 g Vitamin D 100 CWS (Roche® #65242) encapsulated powder, 9.3 g Vitamin B 6 , 6.2 g of 10% triturated folic acid, 30.9 g of 1 % triturated Vitamin B ⁇ 2 , 40.1 g dissolution aid (AC DI-SOLTM crosscarmellose sodium) and 20.0 g lubricant (magnesium stearate) in a V-blender. The mixture was compressed to form tablets of about 808 mg each.
  • the 808 mg tablets contained about 1000 mg calcium, 583 mg phosphorus, 400 IU Vitamin D, 15 mg Vitamin Be, 1000 meg folic acid and 500 meg Vitamin B 12 per 4 tablets. This mixture ran well on a Manesty B3B rotary tablet press in 7/16" round dies, and exhibited an average tablet hardness of 14.7 kP when compressed with 28.9 kN force.
  • the supplement composition of the present invention provides supplemental calcium and phosphorus in the relative amounts required to simultaneously correct the calcium and phosphorus deficiencies which characterize the demographic group of those women greater than 31 years of age that are in the 50 th percentile or lower in calcium and phosphorus intake.

Abstract

A dietary supplement composition contains phosphorus and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus, and may, optionally, further contain Vitamin D, Vitamin B12, folate and Vitamin B6 provides components that have been linked to bone health.

Description

CALCIUM DIETARY SUPPLEMENT
Field of the Invention
This invention relates to dietary supplements, more particularly to calcium-containing dietary supplements.
Background of the Invention
Mineral and vitamin compositions are routinely used as dietary supplements, either as general nutritional supplements or as therapeutic preparations directed to treat specific medical problems.
Calcium is an important nutrient for growing children to help in bone formation and for adults to help prevent bone loss. Excessive bone loss may lead to a condition known as "osteoporosis", in which decreased bone mass causes the bones to be more brittle and thus more susceptible to fracture. It is widely believed that a chronic shortage of dietary calcium is one factor leading to osteoporosis, see Osteoporosis, Cause,
Treatment, Prevention, U.S. Dept. of Health and Human Services, Public Health Service National Institutes of Health, Maryland 1987. Calcium dietary supplements appear to be of value in helping to prevent osteoporosis.
It also has been suggested that, in addition to calcium, other minerals, such as copper, magnesium and zinc, and certain vitamins, such as vitamin D, play important roles in bone formation and metabolism, see, for example, Strause, L., et. al., "The Role of Trace Elements in Bone Metabolism", Nutritional Aspects of Osteoporosis. New York, Raven Press, p. 223-233, 1992. Furthermore, there is evidence that elevated levels of homocysteine (Hey), an amino acid that is formed as a byproduct of metabolism and is found in the blood plasma, provide a better indicator for coronary heart disease than elevated blood cholesterol levels (see McCully, K, The Homocysteine Revolution, New Canaan, CT: Keats Publishing, 1997). It has also been found that the B-complex vitamins administered as nutritional supplements can be effective in reducing plasma levels of Hey.
A possible link between elevated Hey and the progression of osteoporosis can be inferred from the effects of two osteoporosis treatments, hormone replacement therapy (HRT) and raloxifene hydrochloride. HRT is an effective treatment for the prevention of osteoporosis, but has an additional documented effect of reduction of Hey levels as well (see Mijatovic V, van der Mooren MJ, "Homocysteine in postmenopausal women and the importance of hormone replacement therapy", Clin Chem Lab Med 2001 Aug;39(8): 764-7). Raloxifene hydrochloride belongs to a class of drugs described as selective estrogen receptor modulators, and in addition to its well documented benefits in the treatment of osteoporosis, it has been shown in two randomized trials on post-menopausal women to reduce Hey levels (see Saitta A et al, "Cardiovascular effects of raloxifene hydrochloride", Cardiovasc Drug Rev 2001 Spring;19(1):57-74).
It has been postulated that elevated levels of Hey are implicated in many of the diseases associated with aging such as the decline in cognitive abilities, occlusive vascular disease and events leading to osteoporosis by virtue of the formation of adducts with metabolically important molecules, primarily proteins (see Krumdieck CL, Prince CW, "Mechanisms of homocysteine toxicity on connective tissues: implications for the morbidity of aging", J Nutr 2000 Feb;130(2S Suppl.):365S-368S). This irreversible homocysteinylation leads to a reduction or complete loss of function of these proteins which is time and Hey concentration dependent. Thus the reduction of Hey achieved through use of suitably formulated nutritional supplements may retard or prevent the progression of these molecular changes to the point where they are manifested as clinical impairment.
There a continuing interest in providing improved calcium dietary supplements which contain other components in addition to calcium in order to promote healthy bone growth and slow or prevent bone loss.
Summary of the Invention
In a first aspect, the present invention is directed to a dietary supplement composition, comprising phosphorus and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus.
In a second aspect, the present invention is directed to a particulate dietary supplement composition, comprising phosphorus and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus.
In a third aspect, the present invention is directed to a directly compressible dietary supplement composition, comprising phosphorus, from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus, a dissolution aid and a lubricant, wherein said directly compressible dietary supplement composition is capable of being directly compressed to form tablet of dietary supplement composition. In a fourth aspect, the present invention is directed to a dietary supplement composition in tablet form, comprising calcium and phosphorus, wherein the tablet has a total weight of from 400 to 2000 milligrams per tablet and comprises greater than about 200 milligrams calcium per tablet and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus.
In a fifth aspect, the present invention is directed to a liquid dietary supplement composition, comprising calcium and phosphorus, wherein the liquid comprises greater than about 100 milligrams calcium per 100 milliliters of liquid and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus.
In a sixth aspect, the present invention is directed a dietary supplement composition comprising phosphorus, from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus and a compound selected from Vitamin D, Vitamin B12, folate and Vitamin B6.
Comparison of daily calcium intake and daily phosphorus intake set forth in IOM Daily Reference Intakes of Ca, P, Mg and F, 1997, pp. 390- 391 (ISBN 0-309-06403-1 ) with the recommended daily intakes set forth in 21 U.S. Code of Federal Regulations 101.9 reveals a correlation between calcium and phosphorus deficiencies, particularly among women from 31 to 70 years of age and among children from 4 to 8 years of age. The supplement composition of the present invention provides supplemental calcium and phosphorus in the relative amounts required to simultaneously correct the calcium and phosphorus deficiencies which characterize the demographic group of those women greater than 31 years of age that are in the 50th percentile or lower in calcium and phosphorus intake. In preferred embodiments, the supplement composition of the present invention combines the benefits of supplemental calcium and phosphorus in the above described ratios with the effects of certain B-complex vitamins to provide further benefit in the prevention of osteoporosis in men and women.
Detailed Description of Invention and Preferred Embodiments
In a preferred embodiment, the dietary supplement composition of the present invention comprises greater than about 20 parts by weight ("pbw"), more preferably from about 25 to about 35 pbw, and even more preferably from 28 to about 32 pbw calcium per 100 pbw of the supplement composition.
In a preferred embodiment, the supplement composition of the present invention comprises from about 1.4 to about 2.1 pbw, more preferably from about 1.5 to about 2.0 pbw, calcium per pbw phosphorus.
In a preferred embodiment, the calcium component of the supplement composition of the present invention comprises one or more of calcium chelates, such as for example, calcium proteinate, and calcium salts, such as, for example, calcium carbonate, calcium gluconate, calcium citrate, tricalcium phosphate, or dicalcium phosphate dihydrate or anhydrous dicalcium phosphate, calcium citrate maleate.
In a preferred embodiment, the phosphorus component of the supplement composition of the present invention comprises one or more of phosphate salts, such as for example, tricalcium phosphate, or dicalcium phosphate dihydrate or anhydrous dicalcium phosphate, sodium phosphate, and proteins, such as, for example, soy protein, whey protein. ln a preferred embodiment, the phosphorus component and a portion of the calcium component of the supplement composition of the present invention are supplied as a calcium phosphate salt, such as for example, tricalcium phosphate, dicalcium phosphate dihydrate, anhydrous dicalcium phosphate, monocalcium phosphate.
In a preferred embodiment, the calcium and phosphorus components are each in the form of particles, more preferably particles having an average particle size of from about 180 to about 350 micrometers (μm).
In a preferred embodiment, the dietary supplement composition of the present invention comprises anhydrous dicalcium phosphate, tricalcium phosphate and calcium carbonate.
In a highly preferred embodiment, the dietary supplement composition of the present invention comprises, based on 100 pbw of the composition, from about 50 to about 70 pbw, more preferably from about 56 to about 65 pbw, and even more preferably from about 59 to about 62 pbw, anhydrous dicalcium phosphate, from about 24 to about 40 pbw, more preferably from about 28 to about 36 pbw, and even more preferably from about 31 to about 33 pbw, tricalcium phosphate and from about 3 to about 11 pbw, more preferably from about 5 to about 9 pbw, and even more preferably from about 6 to about 8 pbw, calcium carbonate.
In a preferred embodiment, the dietary supplement composition is capable of being directly compressed to form a compressed oral dosage from, such as, for example, a tablet or caplet, and comprises, based on 100 pbw of the composition, from about 50 to about 70 pbw, more preferably from about 56 to about 65 pbw, and even more preferably from about 59 to about 62 pbw, anhydrous dicalcium phosphate, from about 24 to about 40 pbw, more preferably from about 28 to about 36 pbw, and even more preferably from about 31 to about 33 pbw, tricalcium phosphate and from about 3 to about 11 pbw, more preferably from about 5 to about 9 pbw, and even more preferably from about 6 to about 8 pbw, calcium carbonate, from about 1 to about 3 pbw dissolution aid, and from about 0.5 to about 2 pbw lubricant.
In a preferred embodiment, the supplement composition further comprises dietary supplemental amounts of vitamins or minerals other than calcium or phosphorus. In a highly preferred embodiment, the supplement composition comprises a dietary supplemental amount of one or more vitamins, such as for example, vitamin D, Vitamin B6; folate and Vitamin Bι2, phytoestrogens, such as for example, one or more isoflavones, one or more probiotics and prebiotics, such as for example lactobacillus acidophilus, inulin or other polysaccharides and one or more minerals other than calcium or phosphorus, such as for example, boron, copper, zinc, magnesium, manganese and zinc, that play a role in bone formation and/or bone metabolism. Alternatively, the supplement composition of the present composition may be included as a component of a multi-vitamin and mineral supplement composition.
In one embodiment, the dietary supplement composition comprises calcium and phosphorus and further comprises one or more of Vitamin D, Vitamin B6, folate and Vitamin B-ι2.
In a preferred embodiment, the composition comprises, based on 100 pbw of the composition, from about 6.2 to about 62 pbw, more preferably from about 15.5 to about 47 pbw, and even more preferably from about 29 to about 33 pbw, calcium and from about 6.2 to about 55.7 pbw, more preferably from about 9.3 to about 55.7 pbw and even more preferably from about 16 to about 20 pbw, phosphorus.
In a preferred embodiment, the composition comprises, based on 100 pbw of the composition, from about 0.000039 to about 0.0012 pbw, more preferably from about 0.00019 to about 0.00062 pbw, and even more preferably from about 0.00025 to about 0.00035 pbw, Vitamin D (as cholecalciferol).
In a preferred embodiment, the composition comprises, based on
100 pbw of the composition, from about 0.03 to about 6.2 pbw, more preferably from about 0.15 to about 4.64 pbw, and even more preferably from about 0.30 to about 0.60 pbw, Vitamin Be.
In a preferred embodiment, the composition comprises, based on
100 pbw of the composition, from about 0.0016 to about 0.062 pbw, more preferably from about 0.0062 to about 0.046 pbw and even more preferably from about 0.025 to about 0.035 pbw, folate (as folic acid);
In a preferred embodiment, the composition comprises from about
0.000031 to about 0.037 pbw , more preferably from about 0.00019 to about 0.031 pbw and even more preferably from about 0.01 to about 0.03 pbw, Vitamin B-ι2 (as cyanocobalamin).
The supplement composition of the present invention may, optionally, contain other ingredients generally recognized as safe for food additive use, including for example, preservatives, such as, for example, butylated hydroxytoluene, butylated hydroxyanisole, food grade emulsifiers, such as, for example, lecithin, propylene glycol esters, and pharmaceutically acceptable carriers and excipients, such as for example, binders, fillers, lubricants, dissolution aids. The supplement composition of the present invention is made by combining calcium and phosphorus components, as well as any optional components, in the desired relative amounts and mixing the components according to known methods to produce a substantially homogeneous mixture.
The present supplement composition may be administered in any oral dosage form, including liquid dosage forms such as, for example, a suspension or slurry, and oral solid dosage forms such as, for example, a tablet or bulk powder. As used herein the term "tablet" refers generally to tablets, caplets, capsules, including soft gelatin capsules, and lozengers.
In a preferred embodiment, the supplement composition of the present invention is administered in the form of a tablet. More preferably, the supplemental composition is administered in the form of a tablet of less than or equal to 2 grams per tablet, more preferably from 400 to 1900 mg per tablet, which contains greater than about 225 mg, more preferably from about 250 mg to about 800 mg, calcium per tablet.
Tablets are made by methods known in the art and may further comprise suitable binders, lubricants, diluents, disintegrating agents, colorants, flavoring agents, flow-inducing agents, melting agents which are known in the art. The oral solid dosage form may, optionally, have a film coating to protect the components of the supplement composition from one or more of moisture, oxygen and light or to mask any undesirable taste or appearance. Suitable coating agents include, for example, cellulose, hydroxypropylmethyl cellulose. Example 1
The supplement composition of Example 1 was made by mixing 1174.8 grams (g) anhydrous dicalcium phosphate, 629.9 g tricalcium phosphate, 134.7 g calcium carbonate, 40.1 g dissolution aid (AC Dl- SOL™ crosscarmellose sodium) and 20.1 g lubricant (magnesium stearate) in a V-blender. The mixture exhibited a bulk density of 0.859 grams per cubic centimeter and a tamped density of 0.943 grams per cubic centimeter.
The mixture was compressed to form tablets of about 950 mg or about 1900 mg each. The 950 mg tablets each contained about 300 mg calcium and 175 mg phosphorus per tablet. The 1900 mg tablets each contained about 600 mg calcium and 350 mg phosphorus per tablet.
The dissolution properties of the tablets were determined by <711> Dissolution, USP 24, p 1941 (2000) in 0.1 N HCI at 37°C for a test period of 45 minutes. Results are set forth below in TABLE I as tablet weight, expressed in milligrams (mg), results of analysis of the dissolution medium by Inductively Coupled Plasma Spectrophotometer ("ICP Results"), expressed in milligrams of calcium or phosphorus per gram of tablet powder (mg/g), and in milligrams (mg) per 900 milliliters of dissolution medium and the "Label Claim" amount, calculated from the total amount of calcium or phosphorus (in mg) in 900 ml of dissolution medium and expressed as a percentage of the initial tablet weight. TABLE
Tablet # Tablet ICP Results In 900 ml Label Claim
Weight (mg/gm) (mg) (%)
( 9)
Ca P Ca P Ca P
1 946.3 321 195 288.9 175.5 96.3 100.3
944.8 311 188 279.9 169.2 93.3 96.7
940.2 310 188 279.0 169.2 93.0 96.7
4 941.7 315 188 283.5 169.2 94.5 96.7
951.4 322 189 289.8 170.1 96.6 97.2
940.8 320 191 288.0 171.9 96.0 98.2
7 1890.8 583 354 524.7 318.6 87.5 91.0
8 1894.5 570 338 513.0 304.2 85.5 86.9
9 1901.0 582 350 523.8 315.0 87.3 90.0
10 1897.9 572 344 514.8 309.6 85.8 88.5
11 1895.0 534 313 480.6 281.7 80.1 80.5
Example 2
The supplement composition of Example 2 was made by mixing 1148.2 grams (g) anhydrous dicalcium phosphate, 613.7 g tricalcium phosphate, 131.2.7 g calcium carbonate, 0.4 g Vitamin D 100 CWS (Roche® #65242) encapsulated powder, 9.3 g Vitamin B6, 6.2 g of 10% triturated folic acid, 30.9 g of 1 % triturated Vitamin Bι2, 40.1 g dissolution aid (AC DI-SOL™ crosscarmellose sodium) and 20.0 g lubricant (magnesium stearate) in a V-blender. The mixture was compressed to form tablets of about 808 mg each. The 808 mg tablets contained about 1000 mg calcium, 583 mg phosphorus, 400 IU Vitamin D, 15 mg Vitamin Be, 1000 meg folic acid and 500 meg Vitamin B12 per 4 tablets. This mixture ran well on a Manesty B3B rotary tablet press in 7/16" round dies, and exhibited an average tablet hardness of 14.7 kP when compressed with 28.9 kN force.
The supplement composition of the present invention provides supplemental calcium and phosphorus in the relative amounts required to simultaneously correct the calcium and phosphorus deficiencies which characterize the demographic group of those women greater than 31 years of age that are in the 50th percentile or lower in calcium and phosphorus intake.

Claims

Claims:
1. A dietary supplement composition, comprising phosphorus and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus.
2. The composition of claim 1 , wherein the composition comprises greater than about 20 parts by weight calcium per 100 parts by weight of the supplement composition.
3. The composition of claim 1 , wherein the composition comprises from about 25 to about 35 parts by weight calcium per 100 parts by weight of the supplement composition.
4. The composition of claim 1 , wherein the composition comprises from 28 to about 32 parts by weight calcium per 100 parts by weight of the supplement composition
5. The composition of claim 1 , wherein the composition comprises from about 1.4 to about 2.1 parts by weight calcium per part by weight phosphorus.
6. The composition of claim 1 , wherein the composition comprises from about 1.5 to about 2.0 per part by weight calcium per part by weight phosphorus.
7. The composition of claim 1 , wherein the calcium component of the composition comprises one or more compound selected from the group consisting of calcium carbonate, calcium gluconate, calcium citrate, tricalcium phosphate, or dicalcium phosphate dihydrate or anhydrous dicalcium phosphate, calcium citrate maleate
8. The composition of claim 1 , wherein the phosphorus component of the composition comprises one or more compound selected from the group consisting of tricalcium phosphate, dicalcium phosphate dihydrate, anhydrous dicalcium phosphate, monocalcium phosphate.
9. The composition of claim 1 , wherein the phosphorus component and a portion of the calcium component of the supplement composition of the present invention are supplied as one or more compound selected from the group consisting of tricalcium phosphate, dicalcium phosphate dihydrate, anhydrous dicalcium phosphate and monocalcium phosphate.
10. The composition of claim 1 , wherein the composition comprises, based on 100 parts by weight of the composition, from about 50 to about 70 parts by weight anhydrous dicalcium phosphate, from about 24 to about 40 parts by weight tricalcium phosphate, and from about 3 to about 11 parts by weight calcium carbonate
11. The composition of claim 1 , wherein the composition comprises, based on 100 parts by weight of the composition, from about 56 to about 65 parts by weight anhydrous dicalcium phosphate, from about 28 to about 36 parts by weight tricalcium phosphate, and from about 5 to about 9 parts by weight calcium carbonate
12. The composition of claim 1 , further comprising one or more compound selected from the group consisting of vitamin D, Vitamin B6; folate, and Vitamin B12.
13. The composition of claim 1 , wherein the composition is in particulate form.
14. The composition of claim 1 , wherein the composition is in liquid form.
15. The composition of claim 1 , wherein the composition is in tablet form.
16. A directly compressible dietary supplement composition, comprising phosphorus, from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus, a dissolution aid and a lubricant, wherein said directly compressible dietary supplement composition is capable of being directly compressed to form tablet of dietary supplement composition.
17. The composition of claim 16, wherein the composition comprises, based on 100 parts by weight of the composition, from about 50 to about 70 parts by weight, anhydrous dicalcium phosphate, from about 24 to about 40 parts by weight tricalcium phosphate from about 3 to about 11 parts by weight calcium carbonate, from about 1 to about 3 parts by weight dissolution aid, and from about 0.5 to about 2 parts by weight lubricant.
18. The composition of claim 16, wherein the composition comprises, based on 100 parts by weight of the composition, from about 56 to about 65 parts by weight anhydrous dicalcium phosphate, from about 28 to about 36 parts by weight tricalcium phosphate and from about 5 to about 9 parts by weight calcium carbonate, from about 1 to about 3 parts by weight dissolution aid, and from about 0.5 to about 2 parts by weight lubricant.
19. The composition of claim 16, wherein the composition comprises, based on 100 parts by weight of the composition, from about 59 to about 62 parts by weight anhydrous dicalcium phosphate, from about 31 to about 33 parts by weight tricalcium phosphate, from about 6 to about 8 parts by weight calcium carbonate, from about 1 to about 3 parts by weight dissolution aid, and from about 0.5 to about 2 parts by weight lubricant.
20. The composition of claim 16, further comprising one or more compound selected from the group consisting of Vitamin D, Vitamin B6; folate and Vitamin B12.
21. A dietary supplement composition in tablet form, comprising calcium and phosphorus, wherein the tablet has a total weight of from 400 to 2000 milligrams per tablet and comprises greater than about 200 milligrams calcium per tablet and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus.
22. The dietary supplement composition of claim 21 , wherein the tablet has a total weight of from 400 to 1900 mg per tablet and contains greater than about 225 mg calcium per tablet.
23. The dietary supplement composition of claim 21 , wherein the tablet has a total weight of from 400 to 1900 mg per tablet and contains from about 250 mg to about 800 mg calcium per tablet.
24. The composition of claim 21 , further comprising one or more compound selected from the group consisting of Vitamin D, Vitamin B6; folate and Vitamin B-ι2.
25. A liquid dietary supplement composition, comprising calcium and phosphorus, wherein the liquid comprises greater than about 100 milligrams calcium per 100 milliliters of liquid and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus.
26. The composition of claim 1 , further comprising one or more compound selected from the group consisting of Vitamin D, Vitamin B6; folate and Vitamin
27. A dietary supplement composition comprising phosphorus, from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus and one or more compounds selected from the group consisting of Vitamin D, Vitamin B-t2, folate and Vitamin B&.
PCT/US2002/025146 2001-08-09 2002-08-08 Calcium dietary supplement WO2003013270A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002331013A AU2002331013A1 (en) 2001-08-09 2002-08-08 Calcium dietary supplement

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31100801P 2001-08-09 2001-08-09
US60/311,008 2001-08-09

Publications (2)

Publication Number Publication Date
WO2003013270A2 true WO2003013270A2 (en) 2003-02-20
WO2003013270A3 WO2003013270A3 (en) 2003-10-09

Family

ID=23204979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025146 WO2003013270A2 (en) 2001-08-09 2002-08-08 Calcium dietary supplement

Country Status (3)

Country Link
US (1) US6790462B2 (en)
AU (1) AU2002331013A1 (en)
WO (1) WO2003013270A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110354138A (en) * 2019-07-18 2019-10-22 宿迁市现代生物科技股份有限公司 A kind of formula of the granular calcium carbonate of the directly compressible of low abrasion

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037065A1 (en) * 1999-05-27 2005-02-17 Drugtech Corporation Nutritional formulations
WO2000072831A1 (en) * 1999-05-27 2000-12-07 Drugtech Corporation Nutritional formulations
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use
US7025998B2 (en) * 2003-05-30 2006-04-11 Rotta Research Laboratorium S.P.A. Phytoestrogens and probiotic for women's health
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
HUE033015T2 (en) * 2004-05-04 2017-11-28 Innophos Inc Directly compressible tricalcium phosphate
DE102005022953A1 (en) * 2005-05-19 2006-11-23 Chemische Fabrik Budenheim Kg Dietary supplements
US7998500B2 (en) * 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) * 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) * 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
GB0522045D0 (en) * 2005-10-28 2005-12-07 Novartis Ag Pharmaceutical compositions
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
ES2769583T3 (en) 2007-03-22 2020-06-26 Neurocentria Inc Magnesium compositions and uses thereof
CA2712647C (en) * 2008-01-28 2016-08-30 Beauty Pearl Group Limited Formulas comprising calcium, magnesium, zinc, and vitamin d3 for the prevention and amelioration of osteoporosis
EP2282726A1 (en) * 2008-05-15 2011-02-16 Firmenich S.A. Delivery system for an active ingredient
US20110070337A1 (en) * 2009-09-21 2011-03-24 Whitewave Services, Inc. Reduced Calorie Soy Beverage
ES2725202T3 (en) 2010-06-24 2019-09-20 Prayon S A Stabilized active substance
US9855305B2 (en) 2016-03-29 2018-01-02 Companion Therapeutics Llc Pharmaceutical composition containing combinations of vitamins, minerals, probiotics, and prebiotics effective in preventing adverse effects associated with the use of proton-pump inhibitors
EP3520798A1 (en) 2018-01-31 2019-08-07 Omya International AG Use of functionalized calcium carbonate as active ingredient

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751085A (en) * 1984-08-29 1988-06-14 Gaull Gerald E Human nutritional compositions containing taurine and vitamins and/or minerals
US4781925A (en) * 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
US5340603A (en) * 1993-08-30 1994-08-23 Abbott Laboratories Nutritional product for human infants having chronic lung disease
US5480872A (en) * 1993-05-28 1996-01-02 Abbott Laboratories Method of providing enternal nutritional support to persons infected with human immunodeficiency virus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825033D0 (en) * 1998-11-13 1999-01-13 Nycomed Pharma As Process

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751085A (en) * 1984-08-29 1988-06-14 Gaull Gerald E Human nutritional compositions containing taurine and vitamins and/or minerals
US4781925A (en) * 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
US5480872A (en) * 1993-05-28 1996-01-02 Abbott Laboratories Method of providing enternal nutritional support to persons infected with human immunodeficiency virus
US5340603A (en) * 1993-08-30 1994-08-23 Abbott Laboratories Nutritional product for human infants having chronic lung disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS [Online] CHANDLER ET AL.: 'Investigation of calcium, phosphorus and vitamin D3 relations in rats by multiple regression techniques', XP002964255 Retrieved from STN Database accession no. 1964:63083 & J. NUTR. vol. 78, 1962, pages 28 - 36 *
DATABASE HCAPLUS [Online] GUENTHER ET AL.: 'Effect of vitamin D3 on the useability of mineral phosphorus compounds', XP002964253 Retrieved from STN Database accession no. 1982:51078 & KRAFTFUTTER vol. 64, no. 10, 1981, page 500, 505-506, 508 *
DATABASE HCAPLUS [Online] LEE ET AL.: 'Effect of supplementation of the diets with calcium and calcium-rich foods on bone density of elderly females with osteoporosis', XP002964254 Retrieved from STN Database accession no. 1981:423212 & AMERICAN JOURNAL OF CLINICAL NUTRITION vol. 34, no. 5, 1981, pages 819 - 823 *
'Posture-D', [Online] 1999, XP002964257 Retrieved from the Internet: <URL:www.drugstore.com> *
TVM PLUS (MULTIPLE VITAMIN & MINERAL FORMULA), [Online] 1995, XP002964256 Retrieved from the Internet: <URL:www.cybervitamins.com.com> *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110354138A (en) * 2019-07-18 2019-10-22 宿迁市现代生物科技股份有限公司 A kind of formula of the granular calcium carbonate of the directly compressible of low abrasion

Also Published As

Publication number Publication date
AU2002331013A1 (en) 2003-02-24
US6790462B2 (en) 2004-09-14
WO2003013270A3 (en) 2003-10-09
US20030031726A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
US6790462B2 (en) Calcium dietary supplement
EP0702954B1 (en) Calcium dietary supplement
TWI457079B (en) Multi-vitamin and mineral nutritional supplements
EP1662908B9 (en) Composition and method for facilitating bone healing
US6818228B1 (en) Dietary supplements containing ultradense calcium citrate and carbonyl iron
CA2376017C (en) Potassium calcium citrate compositions and methods for production
US20050037089A1 (en) Method for promoting bone growth
US11596166B2 (en) Compositions and methods for treating aging and/or improving human health
US6489361B1 (en) Phosphorus binder
CA2305190A1 (en) Serotonin containing formulation for oral administration and method of use
RU2379043C2 (en) Pharmaceutical composition for prevention and treatment of menopause osteoporosis in women
US20030096018A1 (en) Multi-vitamin and hormone replacement supplement
US6936286B2 (en) Healthy bone formulation
US20030045510A1 (en) Estrogen-plus
JP2003306443A (en) Cholesterol-reducing peptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP